Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCT1080221878
jRCT1080221878UnknownPhase 1

Pharmacokinetic study of TRK-820 -Pharmacokinetic study among TRK-820 tablets and TRK-820 soft capsules.-

Toray Industries,Inc.0 sites8 target enrollmentStarted: TBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Enrollment
8
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Intervention Model
Single-facility, Randomized, Cross-over, Open Study

Eligibility Criteria

Ages
20age old over to 39age old under (—)
Sex
Male

Inclusion Criteria

  • •Subjects over 20 and under 40 years of age.
  • •Subjects giving consent to enter the clinical trial.

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Unknown
Phase 1
Pharmacokinetic study of TRK-820 -Pharmacokinetic study among TRK-820 tablets and TRK-820 soft capsules.Healthy Japanese Male
JPRN-jRCT1080221878Toray Industries,Inc.8
Unknown
Phase 3
A General Clinical Pharmacological Study of TRK-820 Soft Capsules - Refractory Pruritus in Patients on Peritoneal DialysisIntractable Pruritus in Patients on Peritoneal Dialysis
JPRN-jRCT2080222514Toray Industries,Inc.
Unknown
Phase 3
A General Clinical Pharmacological Study of TRK-820 Soft Capsules - Refractory Pruritus in Patients on Peritoneal Dialysis-Intractable Pruritus in Patients on Peritoneal Dialysis
jRCT2080222514Toray Industries,Inc.
Completed
Phase 1
A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal ImpairmentRenal Impairment
NCT01443429Toray Industries, Inc24
Recruiting
Phase 3
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Takeda59